3TC's clear improvement over AZT

Researchers on Sunday were to present positive results from two European Phase II/III studies of BioChem Pharma Inc.'s 3TC nucleoside analog in AIDS patients, which BCHXF said will allow partner Glaxo to file for worldwide marketing approval in the first half of 1995.

A total of 352 patients were tested in both trials, which produced statistically significant results on three measures: increased CD4 counts, virus levels in blood and in blood plasma serum.